Genmab A/S (GMAB) to Release Earnings on Thursday

Key Points

• Genmab A/S is set to announce its Q2 2025 earnings on August 7th, with expected earnings of $0.39 per share and revenue of $5.77 billion.
• The company's stock has experienced a 1.5% decline, currently trading at $22.27, with a market capitalization of $14.29 billion.
• Analysts have recently upgraded Genmab A/S's rating to "buy" and set a revised price target ranging from $37.00 to $46.00, reflecting a consensus "Moderate Buy" rating.

Genmab A/S (NASDAQ:GMAB - Get Free Report) is anticipated to announce its Q2 2025 earnings results before the market opens on Thursday, August 7th. Analysts expect the company to announce earnings of $0.39 per share and revenue of $5.77 billion for the quarter. Genmab A/S has set its FY 2025 guidance at EPS.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last posted its earnings results on Thursday, May 8th. The company reported $0.31 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.23 by $0.08. The company had revenue of $715.00 million during the quarter, compared to the consensus estimate of $5.17 billion. Genmab A/S had a net margin of 35.11% and a return on equity of 18.08%. On average, analysts expect Genmab A/S to post $1 EPS for the current fiscal year and $2 EPS for the next fiscal year.

Genmab A/S Stock Performance

NASDAQ GMAB traded up $0.11 on Friday, reaching $21.78. 1,204,467 shares of the company's stock traded hands, compared to its average volume of 989,805. The firm has a market cap of $13.97 billion, a price-to-earnings ratio of 12.38, a P/E/G ratio of 6.58 and a beta of 0.95. The stock has a 50 day moving average price of $21.66 and a 200-day moving average price of $20.83. Genmab A/S has a fifty-two week low of $17.24 and a fifty-two week high of $28.43.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on GMAB. HC Wainwright restated a "buy" rating and set a $37.00 target price (down from $50.00) on shares of Genmab A/S in a research report on Wednesday, April 9th. Truist Financial boosted their target price on shares of Genmab A/S from $45.00 to $46.00 and gave the company a "buy" rating in a research report on Tuesday, July 8th. Finally, Wall Street Zen upgraded shares of Genmab A/S from a "hold" rating to a "buy" rating in a research report on Monday. One investment analyst has rated the stock with a sell rating, three have given a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $37.80.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.